NCT02691793View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

PHASE4CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 20, 2017

Primary Completion Date

August 30, 2019

Study Completion Date

November 19, 2019

Conditions
Refractory Solid Tumors
Interventions
DRUG

Sunitinib

sunitinib 37.5mg QD

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02691793 - Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter